We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Two Next Generation Diagnostic Platforms Available in Europe

By LabMedica International staff writers
Posted on 19 Feb 2009
Two next-generation clinical laboratory systems are now commercially available in Europe.

The Vitros 5600 integrated system and the high-capacity Vitros 3600 immunodiagnostic system are next generation platforms that were designed to address the needs of modern clinical labs, giving patients and clinicians high-quality and reliable test results.

The Vitros 5600 system is designed to integrate clinical chemistry and immunoassay testing and can perform more than 100 different chemistry, immunoassay, and infectious disease assays on a single, high-quality system. More...
Individual samples are accessed independently and in parallel for chemistry and immunoassay testing. This approach optimizes turnaround time and productivity by intelligently accounting for variable sample and test mixes. In addition to its current broad menu, which includes user-defined applications, the Vitros 5600 integrated system will be able to run new tests for earlier detection of diseases.

The Vitros 3600 immunodiagnostic system is designed for medium- to high-volume labs. Three Vitros technologies are combined into a single system: Microwell technology that with enhanced chemiluminescence enables exceptional assay performance with small sample volume requirements across a broad range of diseases; MicroSensor technology that automatically performs sample quality indices checks on the immunoassay system; and Intellicheck technology that verifies analytical performance and reduces error potential by providing real-time operator notification and tracking.

The systems were developed by Ortho Clinical Diagnostics (High Wycombe, UK). David Atkins, Ph.D., vice president of Ortho Clinical Diagnostics, said, "Our mission has always been to give health professionals the highest quality tools to determine the best treatment. The introduction of the Vitros 5600 integrated system and Vitros 3600 immunodiagnostic system continues this mission with next generation instruments that have a broad, world class menu of assays and the capacity to support future high-impact tests."

Ortho-Clinical Diagnostics, Inc., a Johnson & Johnson company, delivers high quality in-vitro diagnostic products that give health care professionals around the world the knowledge they need to make better treatment decisions sooner.

Related Links:

Ortho Clinical Diagnostics




New
Gold Member
STI Test
Vivalytic MG, MH, UP/UU
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
HIV-1 Molecular Diagnostic Assay
AltoStar HIV RT-PCR Kit 1.5
New
All-in-One Molecular System
AIO M160
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Accurate immunotherapy selection for esophageal and GEJ carcinomas depends on consistent PD-L1 assessment (credit: Adobe Stock)

FDA Approval Expands Use of PD-L1 Companion Diagnostic in Esophageal and GEJ Carcinomas

Esophageal and gastroesophageal junction carcinomas (GEJ) have a poor prognosis, with approximately 16,250 deaths in the United States in 2025 and a five-year relative survival of 21.9%.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.